ArticleFrontiers in oncology2025
Follicular dendritic cell sarcoma: a great mimicker with unpredictable clinical course-experience from a tertiary care cancer center in India.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Case report of a giant hypervascular mediastinal mass with airway and SVC compromise managed without preoperative biopsy.Frontiers in oncology · 2026Article
- Primary hepatic follicular dendritic cell sarcoma: A case study and literature review.The Journal of international medical research · 2025Review
- Refractory extra nodal follicular dendritic cell sarcoma in a young male exhibiting a marked response to gemcitabine and docetaxel: A case report and literature review.Medicine internationalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Follicular dendritic cell sarcoma (FDCS) is a rare mesenchymal malignant tumor derived from follicular dendritic cells. FDCS arises mainly from lymph nodes and rarely are extranodal. Diagnostic dilemma occurs due to the same micromorphology as other sarcomas and lymphomas. Curative radical resection is the standard therapy, and adjuvant treatment is not defined. For unresectable disease, chemotherapy and radiotherapy are indicated with variable response rates. Due to its rarity, a standard treatment is not yet defined. Objective: This study aims to analyze the clinicopathological features, treatment patterns, and survival outcome of FDCS cases in our institution. Methodology: The study was conducted in the Department of Medical Oncology State Cancer Institute, Sher I Kashmir Institute of Medical Sciences (SKIMS), Srinagar, Jammu and Kashmir, India. Biopsy-proven FDCS patients were identified through the hospital-based registry from January 1, 2020 to December 31, 2023. Results: A total of six patients were diagnosed during the study period. The median age was 28 years (range, 21-51 years). There were four male and two female patients, with male-to-female ratio of 2:1. Common symptoms were abdominal pain (50%) and cough and dyspnea (33.3%). Four patients (66.6%) had nodal involvement with retroperitoneum and mediastinum in two cases each. Three patients had extranodal involvement, with the colon in two and with the liver in one. Five patients were initially misdiagnosed as non-Hodgkin's lymphoma, soft tissue sarcoma, neurogenic tumor, and carcinoma. The treatments offered were surgery, chemotherapy, targeted therapy, radiotherapy, and observation. Four patients were alive at a median follow-up of 12 months, with three patients having no evidence of disease and one case living with the disease. Two patients had succumbed to the disease. Conclusion: The study described the clinicopathological characteristics, diagnostic challenges, and management difficulties in FDCS patients. Due to the rarity of this disease, high expertise is needed to diagnose FDCS; otherwise, the diagnosis usually gets delayed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.